Clinical Trial Update: Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating an ibrutinib lead-in followed by venetoclax plus ibrutinib in relapsed/refractory chronic lymphocytic leukemia. The study status is t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED